Tesamorelin / Ipamorelin Blend — GHRH (1-44) GHSR | Research Grade

The Tesamorelin Ipamorelin blend pairs a 44-amino-acid GHRH analog with a selective GHRP in a single research vial — designed for researchers studying the synergistic GH release that occurs when GHRH and GHRP receptors are activated simultaneously. Research-grade specs Components: Tesamorelin (GHRH) Ipamorelin (GHRP) Combined mechanism: Dual receptor (GHRH-R GHS-R1a) GH stimulation Studied applications GHRH GHRP synergy research Combined GH-pulse studies Body-composition research with dual mechanism Sleep / GH-release-pattern studies Quality & trust ≥99% HPLC purity, third-party tested Mass spectrometry identity confirmation LAL endotoxin testing on every batch Batch-specific Certificate of Analysis included USA same-day shipping (orders before 2pm CT M-F) Related research: Tesamorelin alone · Ipamorelin alone · CJC-1295 Ipamorelin Research literature Tesamorelin AND Ipamorelin has been the subject of 3 peer-reviewed publications indexed in PubMed. Selected recent literature for research reference: Mendias CL et al. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. PMID: 41966639 Rahman OF et al. (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. PMID: 41490200 Mayfield CK et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. PMID: 41476424 References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.